Update on the Mechanism of Action of Bimatoprost: A Review and Discussion of New Evidence

Survey of Ophthalmology

Volumn 49, Issue 2 SUPPL. 1, 2004, Pages

  Krauss, Achim H P ^a   Woodward, David F ^a  

^a ALLERGAN INC   (United States)

Author keywords

Bimatoprost; Glaucoma; Intraocular pressure; Metabolism; Prostaglandin; Prostamide

Indexed keywords

17 PHENYLPROSTAGLANDIN F2 ALPHA; AMIDE; ANANDAMIDE; ANTIGLAUCOMA AGENT; BIMATOPROST; CYCLOOXYGENASE 2; DRUG METABOLITE; LATANOPROST; NEPAFENAC; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; TRAVOPROST; UNCLASSIFIED DRUG;

AQUEOUS HUMOR; BIOSYNTHESIS; CELL LINE; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; FLUOROPHOTOMETRY; GENE OVEREXPRESSION; GLAUCOMA; HUMAN; HYDROLYSIS; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; PRIORITY JOURNAL; REVIEW;

EID: 1542268218     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.014     Document Type: Article

References (39)

1. Bárány E.H. Simultaneous measurement of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthal. 3:1964;135-143.
2. Basu S., Sjöquist B., Stjernschantz J., Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 50:1994;161-168.
3. Bill A. Conventional and uveo-scleral drainage of aqueous humour in the Cynomolgus Monkey (macaca irus) at normal and high intraocular pressures. Exp Eye Res. 5:1966;45-54.
4. Brubaker R.F., Schoff E.O., Nau C.B., et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 131:2001;19-24.
5. Cantor L.B. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Exp Opin Invest Drugs. 10:2001;721-731.
6. Davies S.S., Ju W.-K., Neufeld A.H., et al. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocular Pharmacol Ther. 19:2003;45-54.
7. Dubiner H., Cooke D., Dirks M., et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30 day comparison with the latanoprost. Surv Ophthalmol. 45:2001;S353-S360.
8. Eisenberg D.L., Toris C.B., Camras C.B. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 47:(Suppl 1):2002;S105-S115.
9. Gandolfi S.A., Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:2003;609-614.
10. Hellberg M.R., McLaughlin M.A., Sharif N.A., et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 47:(Suppl 1):2002;S13-S33.
11. Hellberg M.R., Sallee V.L., McLaughlin M.A. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 17:2001;421-432.
12. Hellberg M.R., Ke T.-L., Haggard K., et al. The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2a by human and rabbit ocular tissue. J Ocular Pharmacol Ther. 19:2003;97-103.
13. Higginbotham E.J., Schuman J.S., Goldberg I., et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 120:2002;1286-1293.
14. Ke T.L., Graff G., Spellman J.M., et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 24:2000;371-384.
15. Kelly C.R., Williams G.W., Sharif N.A. Real-time intracellular calcium mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmcol Exp Ther. 304:2003;238-245.
16. Kozak K.R., Crews B.C., Morrow J.D., et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol ester and ethanolamides. J Biol Chem. 277:2002;44877-44885.
17. Kozak K.R., Crews B.C., Ray J.L., et al. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem. 276:2001;36993-36998.
18. Laibovitz R.A., Vandenburgh A.M., Felix C., et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 119:2001;994-1000.
19. 2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem. 278:2003;27267-27277.
20. Matsuda S., Kanemitsu N., Nakamura A. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res. 64:1997;707-711.
21. Maxey K.M., Johnson J.L., LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 47:(Suppl 1):2002;S34-S40.
22. Noecker R.S., Dirks M.S., Choplin N.T., et al. A six-month randomized clinical trial comparing the intraocular pressure lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 135:2003;55-63.
23. Parrish R.K., Palmberg P., Sheu W.-P., for the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked evaluation multicenter study. Am J Ophthalmol. 135:2003;688-703.
24. Pate D.W., Jarvinen K., Urtti A., et al. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res. 14:1995;791-797.
25. Richter M., Krauss A.H.-P., Woodward D.F., et al. Morphological changes in the anterior eye segment after long term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 44:2003;4419-4426.
26. 2 ethanolamide. J Pharmacol Exp Ther. 301:2002;900-907.
27. Sharif N.A., Kelly C.R., Crider J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 18:2002;313-324.
28. Sharif N.A., Kelly C.R., Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 44:2003;715-721.
29. Sharif N.A., Williams G.W., Kelly C.R. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 432:2001;211-213.
30. Sherwood M., Brandt J., et al. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 45:(Suppl 4):2001;S361-S368.
31. Sjöquist B., Basu S., Byding P., et al. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos. 26:1998;745-754.
32. Sjöquist B., Johansson A., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung/Drug Res. 49:1999;240-249.
33. Sjöquist B., Stjernschantz J. Ocular and systemic pharma cokinetics of latanoprost in humans. Surv Ophthalmol. 47:(Suppl 1):2002;S6-S12.
34. Sjöquist B., Tajallaei S., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung/Drug Res. 49:1999;225-233.
35. Sjöquist B., Uhlin A., Byding P., Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung/Drug Res. 49:1999;234-239.
36. 2 increases uveoscleral outflow and trabecular outflow facility in the cat. Exp Eye Res. 61:1995;649-657.
37. Williams R.D. Efficacy in bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 19:2002;275-281.
38. Woodward D.F., Krauss A.H., Chen J., et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 45:(Suppl 4):2001;S337-S345.
39. Woodward D.F., Krauss A.H., Chen J., et al. Pharmacological characterization of a novel anti-glaucoma agent. J Pharmacol Exp Ther. 305:2003;772-785.